Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
VBCC Perspectives
The $93,000 Question
By
Yu-Ning Wong, MD, MSCE
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Sipuleucel-T (Provenge) and cabazitaxel (Jevtana) have drawn much attention both for being the first new treatments for advanced prostate cancer since docetaxel (Taxotere) was approved in 2004, and for their high costs. As described in Dr Newcomer’s accompanying piece, they will add significantly to the cost of care for prostate cancer patients.
Read Article
Community Trials Essential to Broad Knowledge
By
Ed Pezalla, MD, MPH
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Several sessions at the recent ASCO meeting considered new standards for community-based oncology research and the development of comparative effectiveness research (CER) methods.
Read Article
Premarket Policies May Generate the Best Value
By
Jayson Slotnik, JD, MPH
Value-Based Care
,
VBCC Perspectives
June 2010, Vol 1, No 2
The Patient Protection and Affordable Care Act (PPACA), which is Congress’ latest attempt to reform our healthcare system, creates 3 new entities that will test new payment methodologies or compare current treatments in an attempt to determine better value for our healthcare dollar.
Read Article
CER: Use, Controversy Both Growing
Comparative Effectiveness Research
,
VBCC Perspectives
June 2010, Vol 1, No 2
Even before enactment of national healthcare reform initiatives, development and implementation of a variety of comparative effectiveness research (CER) was well under way, even if it was not specifically called comparative effectiveness.
Read Article
Reaching for Consistency with Genetic Testing
By
Winston Wong, PharmD
Value-Based Care
,
VBCC Perspectives
June 2010, Vol 1, No 2
Recent articles in the
New England Journal of Medicine
1
and the
Journal of the American Medical Association
2
note the tremendous increase in the cost of cancer care, which has at least doubled since 1990. The reasons for this steep increase have been attributed to the release and utilization of new medications, in tandem with more sophisticated surgery and radiation techniques.
Read Article
Compendia: Powerful Tools, Wrong Job
By
Lynn Nishida, RPh
Value-Based Care
,
VBCC Perspectives
May 2010, Vol 1, No 1
At the most basic level, compendia are drug information resources intended to aid clinicians in making “informed treatment decisions, especially in difficult and complex cases.”
1
They were not intended for use in determining reimbursement of medications for the public and private healthcare insurance sectors. Nevertheless, this responsibility was assigned by the Centers for Medicare & Medicaid Services (CMS) in a 1993 law that requires Medicare plans to use 1 of 4 national compendia to determine coverage and pay for “off-label uses of anticancer drugs for Medicare beneficiaries.”
Read Article
Traditional Managed Care Tools Just Don’t Work in Oncology
By
Peter G. Ellis, MD
Value-Based Care
,
VBCC Perspectives
May 2010, Vol 1, No 1
As payers focus on the rising cancer care spend, they are turning to tools previously applied to other diseases. Each seems to have potential, but upon closer review, these have fundamental shortcomings when used for cancer.
Read Article
Evidence-based Medicine: A First Step on the Path to Value
Value-Based Care
,
VBCC Perspectives
May 2010, Vol 1, No 1
The 2007 annual meeting summary of the Institute of Medicine (IOM) succinctly highlighted the issue of variability in care.
Read Article
Page 5 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma